Hans-Peter Schupp
SwitzerlandInvestorMale7.0Global Dominance: 0.00%Hans-Peter Schupp is an investor at the Fidecum fund management company, noted for his analysis of BASF's potential acquisition of Evonik amid a challenging chemical market, highlighting the anticyclical nature of the move.
Power749
Reach9,266
Country presence
Recent news mentions
Hans-Peter Schupp from the Fidecum investment company has invested about 4% of the capital in BASF.
BASF greift nach Evonik und trotzt damit der schlechten ChemiekonjunkturNeue Zürcher Zeitung·Switzerland· 2026-09-27
Switzerland· 2026-09-27
